Journal of the Serbian Chemical Society

JSCS@tmf.bg.ac.rs • www.shd.org.rs/JSCS

J. Serb. Chem. Soc. *88* (9) 825–840 (2023)
JSCS–5665

Original scientific paper
Published 9 September 2023

Evaluation of derivatives of 2,3-dihydroquinazolin-4(1*H*)-one as inhibitors of cholinesterases and their antioxidant activity: *In vitro*, *in silico* and kinetics studies

OLUWATOYIN BABATUNDE[1], SHEHRYAR HAMEED[1], KINGSLEY ADIBE MBACHU[1,2], FAIZA SALEEM[1], SRIDEVI CHIGURUPATI[3], ABDUL WADOOD[4], ASHFAQ UR REHMAN[4], VIJAYAN VENUGOPAL[5], KHALID MOHAMMED KHAN[1,7]*, MUHAMMAD TAHA[7], OLUSEGUN EKUNDAYO[2] and MARIA AQEEL KHAN[6]

[1]H. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan, [2]Department of Chemistry, University of Ibadan, Nigeria, [3]Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraydah-52571, Saudi Arabia, [4]Department of Biochemistry, Computational Medicinal Chemistry Laboratory, UCSS, Abdul Wali Khan University, Mardan, Pakistan, [5]Faculty of Pharmacy, AIMST University, Kedah-08100, Malaysia, [6]Third World Center for Science and Technology, H. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan and [7]Department of Clinical Pharmacy, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam, 31441, Saudi Arabia

(Received 6 November 2021, revised 17 May 2022, accepted 2 February 2023)

Abstract: In search of potent inhibitors of cholinesterase enzymes and antioxidant agents, synthetic derivatives of dihydroquinazolin-4(1*H*)-one (**1**–**38**) were evaluated as potential anti-Alzheimer agents through *in vitro* acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitions and radical (DPPH and ABTS) scavenging activities. The structure–activity relationship (SAR) was mainly based on the different substituents at the aryl part which showed a significant effect on the inhibitory potential of enzymes and radical scavenging activities. The kinetic studies of most active compounds showed a noncompetitive mode of inhibition for AChE and a competitive mode of inhibition for the BChE enzyme. Additionally, molecular modelling studies were carried out to investigate the possible binding interactions of quinazolinone derivatives with the active site of both enzymes.

Keywords: quinazolinone; dual inhibitors; acetylcholinesterase; butyrylcholinesterase; antioxidant; *in vitro*; *in silico*; kinetic studies.

* Corresponding author. E-mail: khalid.khan@iccs.edu; drkhalidhej@gmail.com
https://doi.org/10.2298/JSC211106005B

Available on line at www.shd.org.rs/JSCS/

(CC) 2023 SCS.

INTRODUCTION

In the central nervous system (CNS), one of the preeminent neurotransmitters is acetylcholine (ACh) which is related to memory and cognition. Insufficient ACh levels in the CNS can lead to diseases such as Alzheimer's disease (AD).[1] AD is the most common cause of dementia in elderly people and is characterized by several impaired cortical functions, including judgment, memory loss, comprehension, orientation, language deficit, and learning capacity.[2] The predominant symptoms of all types of dementia are thought to be associated with the gradual decline of broad and compact cholinergic innervation of the human cerebral cortex. This decline contributes to the behavioural and cognitive deficits in AD and is also linked with the reduced levels of neurotransmitters, choline acetyltransferase, acetylcholinesterase (AChE) and Ach.[3] AChE and butyrylcholinesterase (BChE) enzymes are hydrolytic enzymes that act on the neurotransmitter ACh by cleaving it into choline and acetate, thereby stopping their action in the synaptic cleft.[4] Both enzymes are found in amyloid plaques and neurofibrillary tangles in the brain.[5] AChE is the most important enzyme that regulates the level of acetylcholine in a healthy brain, while BChE plays an insignificant role. In AD patients, the AChE activity decreases, BChE activity increases and the ratio between AChE and BChE varies from normal to high levels (0.6–11) in the cortical regions of the brain that affect the disease.[6,7] These observations lead to the concept of dual inhibition, and the most effective treatment approach has been suggested to increase ACh levels and limit cholinergic function by inhibiting AChE and BChE enzymes.

Quinazolinones are extensively explored and are considered important as bioactive synthetic molecules for the development of novel therapeutic agents.[8] Quinazolinone belongs to the *N*-containing fused heterocyclic compounds is a quinazoline with a carbonyl group in the C_4N_2 ring. There are two isomers possible: 4-quinazolinone and 2-quinazolinone; however, the 4-quinazolinone isomer is more common.[9] These compounds have raised universal concerns due to their broad and pronounced biopharmaceutical activities.[10] Many substituted quinazolinones have a broad range of bioactivities such as antimicrobial, antimalarial, antifungal, antiprotozoal, anticancer, antiviral, anti-inflammatory, anti-tubercular, anticonvulsant, diuretic, acaricidal, muscle relaxant, antidepressant, weedicide and many other biological activities.[11] Quinazolinone compounds are also used in the syntheses of a variety of functional substances for synthetic chemistry and are also present in various drugs (Fig. 1).[12]

Antioxidant compounds exhibit an important part as health protection factors.[13] Free radicals are ions, atoms or molecules possessing an unpaired electron such as hydroxyl, nitric oxide, and superoxide which are called reactive oxygen species (ROS).[14] ROS are generated in the human body and can damage DNA, proteins, and lipids, which may lead to different complications such as inflame-

(CC) 2023 SCS.

mation, toxicity and carcinogenesis. Plants-derived antioxidants include carotenes, phytoestrogens, vitamin C, vitamin E and phytates.[15] Furthermore, chronic diseases which are life-limiting, such as diabetes, cancer, arteriosclerosis, AD, and aging, are developed by radical reactions.[16] Natural or synthetic antioxidants compounds terminate the chain reactions by interacting with free radicals before essential molecules are damaged.[17] Thus, the synthesis of new potent antioxidant compounds is of vital importance for rapidly quantifying the effectiveness of antioxidants in disease prevention.



Fig. 1. Pharmacological importance of quinazolinone-based drugs.

Our research group is continuously doing efforts in search of lead compounds for two decades to discover new enzyme inhibitors.[18–21] Previously, we have explored a large number of potent inhibitors based on quinazoline derivatives, including *α*-amylase, *α*-glucosidase,[22,23] *β*-glucuronidase[24] and antileishmanial activities.[25] These heterocycles are reported to possess various significant biological activities. Derivatives of dihydroquinazolin-4(1*H*)-one, in particular, has drawn more and more attention for synthesizing pharmaceuticals and in the field of agrochemicals. Herein we are going to report dihydroquinazolin-4(1*H*)-ones as a new class of inhibitors against acetylcholinesterase, butyrylcholinesterase enzymes and with its antioxidant potential (Fig. 2). In this study, dihydro-



Fig. 2. Rationale of the current study.

(CC) 2023 SCS.

quinazolin-4(1*H*)-ones (**1**–**38**, Table I) have been reported as antioxidant agents and potent cholinesterase inhibitors which may improve clinical outcomes for the development of anti-AD agents.

EXPERIMENTAL

Materials and methods

All enzymes were purchased from Sigma–Aldrich and used without further purification. The acetylcholinesterase enzyme from *Electrophorus electricus* (electric eel) supplied by Sigma–Aldrich (GmbH, USA) whereas butyrylcholinesterase from equine serum procured from Sigma–Aldrich, SRE020; 5,5-dithio-bis-nitrobenzoic acid (DTNB), acetylthiocholine iodide 99 % (ATChI), donepezil hydrochloride were obtained from Sigma–Aldrich. All reagents were purchased from Merck and Sigma–Aldrich. Thin-layer chromatography was carried out on precoated silica gel, GF-254 (Merck). Spots were visualized under ultraviolet light at 254 and 366 nm or iodine vapors. EI- and HREI-MS spectra were recorded on MAT 312 and MAT 113D mass spectrometers. The ^{1}H- and ^{13}C-NMR were recorded on Bruker AM spectrometers, operating at 300 and 400 MHz. The chemical shift (δ) values are presented in ppm, relative to tetramethylsilane (TMS) as an internal standard, and the coupling constant (J) is in Hz.

Cholinesterase enzyme activity

The *in vitro* AChE and BChE inhibitory activity was measured using the methods described earlier.[26] Briefly, stock solutions (1 mg/mL) of test compounds were prepared using 0.01 % DMSO. Working solutions (0.01–100 μg/mL) were prepared by serial dilutions. The various concentrations of test compounds (10 μL) were pre-incubated with sodium phosphate buffer (0.1 M; pH 8.0; 150 μL); AChE solution/ BChE (0.1 U/mL; 20 μL) for 15 min at 25 °C and addition of DTNB (10 mM; 10 μL). The reaction was initiated by the addition of ATChI (14 mM; 10 μL). The reaction mixture was mixed using a cyclomixer and incubated for 10 min at room temperature. The absorbance was measured using a microplate reader at 410 nm wavelength against the blank reading containing 10 μL DMSO instead of the test compound. The inhibition was calculated in %:

$$\text{Inhibition} = 100(1 - \text{absorbance sample}/\text{absorbance control}) \quad (1)$$

and the IC_{50} was calculated. Donepezil (0.01–100 μg/mL) was used as the positive control.

Kinetic study assay

In derivatives of 2,3-dihydroquinazolin-4(1*H*)-one, seven compounds, **2**, **3**, **4**, **10**, **16**, **28** and **34** were selected for kinetic studies, based on their lower IC_{50} values (23.08 to 27.57 μM). In kinetic studies, we used acetyl thiocholine iodide (ATCI)/butyrylthiocholine iodide (BTCI) as a substrate at various concentration (0.175, 0.35, 0.7 and 1.40 mM) and different concentration of AChE/BChE inhibitors (0, 0.625, 1.25 and 2.5 μM) were applied. Enzyme inhibition kinetic mechanisms were determined by using Sigma Plot 14.0 software. The rate of substrate and inhibitor reactions was calculated. Based on the rate of reactions, the software showed the type of enzyme kinetics mechanism. Kinetic studies have shown all the compounds followed as non-competitive type inhibitors (Table I). The types of inhibition of AChE/BChE were determined by Lineweaver Burk plots. The reciprocal of the rate of the reaction was plotted against the reciprocal of substrate concentration to monitor the effect of the inhibitor on both K_m and highest inhibition rate, V_{max}, values. K_m is also known as the Michaelis constant representing the substrate concentration at which the reaction rate is 50 % of the V_{max}.

Available on line at www.shd.org.rs/JSCS/

(CC) 2023 SCS.

Radical scavenging assay

DPPH (2,2-diphenyl-1-picrylhydrazyl) radical activity. Preparation of DPPH solution was adopted from Molyneux[27] and Blois[28] with minor modification. All the test compounds were dissolved in 95 % ethanol. Briefly, 0.5 mL of test compounds were added (0 – blank control, 10, 25, 50, 100, 250, 500 and 1000 g/mL) to 0.5 mL of DPPH (2 μM in 95 % ethanol) and the mixture was incubated at room temperature for 30 min. The absorbance was measured at 517 nm,[29] and the percentage inhibition of test compounds was calculated using the following equation using Microsoft Excel software (version 2010):

$$\text{Scavenging} = 100(1–(\text{absorbance sample}/\text{absorbance control})) \tag{2}$$

Ascorbic acid was used as the positive control.

The IC_{50} (half maximal inhibitory concentration) was calculated by constructing a non-linear regression graph between inhibition *vs.* concentration, using Graph Pad Prism software (version 5).

ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) free-radical cation activity. The ABTS free radical cation scavenging ability of the synthesized compounds was determined according to the procedure described earlier.[30] ABTS was dissolved in distilled water (7×10^{-3} M) and potassium persulphate (2.45×10^{-3} M) was added. This reaction mixture was left overnight (12–16 h) in the dark at room temperature. Various concentrations of test substances (1000, 500, 250, 100, 50, 25 and 10 μg/mL) were incubated with the $ABTS^+$ solution for 30 min. The absorbance was measured at 734 nm, the inhibition was calculated using Eq. (1) and the IC_{50} was calculated. Ascorbic acid was used as the positive control.

Molecular docking protocol

Acetylcholinesterase and butyrylcholinesterase. Molecular docking was performed using molecular operating environment (MOE)[31] to explore the binding mode of the synthetic compounds against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes. First, the 3D structures for all the compounds were generated using the MOE-builder module. Next, the compounds were protonated, and energy was minimized using the default parameters of the MOE. The structural coordinates for AChE and BChE was retrieved from protein databank (PDB code; 1acl & 1p0p). All the structures were subjected to MOE for preparation. Further, the protonation was done using default parameters of the structure preparation module of MOE. Next, the energy was minimized for both the coordinates to get minimal energy conformation. Finally, the refined structures were used for the docking study using the default parameters of MOE. Before running the docking protocol, we have selected a total of often conformations for each compound. The top-ranked conformations based on docking score (*S*) were selected for the protein–ligand interaction (PL) analysis.

RESULTS AND DISCUSSION

Chemistry

Dihydroquinazolin-4(1*H*)-ones **1**–**38** were synthesized by treating isatoic anhydride, substituted aldehyde, and aniline under reflux for 3 h. The reaction was carried out in acetic acid as a solvent at 80–90 °C, Scheme 1. After the reaction completion, it was cooled to room temperature. The solution was added to ice water to form a precipitate. The mixture was filtered and the crude product was washed continuously with an excess of water. The obtained crude product was washed with different solvents to remove impurities, on crystallization from etha-

(CC) 2023 SCS.

nol gave the corresponding pure products having 60–85 % yields.[23] The molecular structures of all compounds **1**–**38** were identified by EI-MS, HREI-MS, ^{1}H- and ^{13}C-NMR.



Scheme 1. Synthesis of dihydroquinazolin-4(1*H*)-ones **1**–**38**.

In vitro *AChE, BChE inhibitions and antioxidant activities*

All synthetic dihydroquinazolin-4(1*H*)-ones **1**–**38** were screened for *in vitro* acetylcholinesterase and butyrylcholinesterase inhibitions, and antioxidant activities. All compounds exhibited good to moderate inhibitory activities in the range of IC_{50} values 23.08–89.7 and 26.01–89.7 µM against AChE and BChE inhibitions, and 16.33–96.65 and18.01–94.97 µM against DPPH and ATBS activities when compared to the donepezil (IC_{50} = 15.08±0.07 µM) and ascorbic acid as the standards (IC_{50} = 15.08±0.07 and 16.09±0.17µM), respectively (Table I). The structure–activity relationship (SAR) proposed that all structural features such as benzene ring, carbonyl group, quinazoline moiety, phenyl ring and aryl ring "R" were taking part in the activity, and due to the presence of different groups "R" at the aryl part some significant fluctuation in the activity was observed (Fig. S-3 of the Supplementary material to this paper).

TABLE I. *In vitro* acetylcholinesterase, butyrylcholinesterase activity, and antioxidant activity (IC_{50} ± SEM^a in μM, SEM – standard error of the mean) after using dihydroquinazolin--4(1*H*)-one derivatives **1**–**38**; NA – not active

Compd. No.	R	AChE activity	BChE activity	DPPH radical activity	ABTS radical activity
1	4-Cl (C_6H_4)	35.04±0.20	37.13±0.18	41.7±0.06	42.97±0.19
2	2-Cl (C_6H_4)	23.08±0.03	26.08±0.43	17.65±0.23	19.47±0.03
3	2,6-Cl (C_6H_3)	24.94±0.12	27.13±0.08	30.7±0.06	32.97±0.19
4	2,4-Cl (C_6H_3)	24.57±0.07	27.57±0.07	16.33±0.02	18.01±0.12
5	2-OH, 3,5-Cl (C_6H_2)	61.89±0.12	67.91±0.18	57.33±0.02	58.01±0.12
6	2-Cl, 6-NO_2 (C_6H_3)	NA	NA	70.7± 0.06	71.97± 0.19
7	5-Cl, 2-OH (C_6H_3)	81.94±0.12	82.13±0.08	83.57±0.17	83.68±0.36
8	3,5-OCH_3 (C_6H_3)	NA	NA	96.65±0.03	94.47±0.13
9	2,5-OCH_3 (C_6H_3)	88.15±0.12	87.15±0.12	84.04±0.02	85.99±0.09
10	2,6-OCH_3 (C_6H_3)	26.94±0.12	27.99±0.09	24.33±0.02	25.01±0.12
11	3,4-OCH_3 (C_6H_3)	87.27±0.18	86.08±0.43	87.57±0.08	89.27±0.18
12	2-Br, 4,5-OCH_3 (C_6H_3)	67.91±0.18	69.02±0.11	51.65±0.03	52.47±0.13
13	2,4-OCH_3 (C_6H_3)	89.7±0.16	85.97±0.19	82.17±0.14	82.01±0.09

(CC) 2023 SCS.

TABLE I. Continued

Compd. No.	R	AChE activity	BChE activity	DPPH radical activity	ABTS radical activity
14	3,4,5-OCH_3 (C_6H_2)	NA	NA	86.65±0.23	87.47±0.03
15	2,3,4-OCH_3 (C_6H_2)	NA[b]	NA[b]	83.33±0.02	85.01±0.12
16	3-OC_2H_5, 4-OCH_3 (C_6H_3)	27.57±0.07	29.13±0.18	30.04±0.02	31.99 ±0.09
17	3-OCH_3, 4-OC_2H_5	NA[b]	NA[b]	92.7± 0.06	94.97± 0.19
18	3,5-OCH_3, 4-OH (C_6H_2)	87.27± 0.18	89.7± 0.16	83.46± 0.03	84.61± 0.11
19	4-Br, 3,5-OCH_3 (C_6H_2)	83.08±0.03	84.94±0.12	76.33±0.02	79.01±0.12
20	4-F, 3-OCH_3 (C_6H_3)	51.94±0.12	53.33±0.02	48.65±0.23	49.47±0.03
21	3-Br, 2-OCH_3 (C_6H_3)	89.17±0.16	88.33±0.12	81.7±0.06	85.97±0.19
22	2-F, 4-OCH_3 (C_6H_3)	27.91±0.18	29.02±0.11	31.33±0.12	32.01±0.12
23	2-Cl, 3-OCH_3 (C_6H_3)	88.15±0.12	87.13±0.12	83.04±0.02	84.99±0.09
24	3-OC_2H_5, 2-OH (C_6H_3)	61.01±0.17	64.57±0.07	49.84±0.03	52.71±0.11
25	2-OCH_2 (C_6H_5)	NA	NA	72.7±0.06	74.97±0.19
26	3-OCH_2 (C_6H_5), 4-OCH_3 (C_6H_3)	NA	NA	88.89±0.10	89.09±0.09
27	4-OCH_2 (C_6H_5)	NA	NA	84.89±0.20	89.09±0.19
28	4-Br (C_6H_4)	25.33±0.02	26.27±0.18	27.33±0.02	28.01±0.12
29	4-CF_3 (C_6H_4)	NA	NA	92.13±0.08	92.79±0.17
30	2-Thiophene	43.08±0.03	46.08±0.43	47.65±0.23	49.47±0.03
31	3-Bromo, 4-OH (C_6H_3)	85.33±0.02	87.47±0.13	83.01±0.07	83.11±0.15
32	4-OCH_3, 3-OH (C_6H_3)	77.27±0.18	75.04±0.52	71.7±0.06	72.97±0.19
33	3-OH (C_6H_4)	47.17±0.15	48.15±0.12	42.33±0.12	43.01±0.12
34	2-OH (C_6H_4)	27.57±0.07	29.02±0.11	28.46±0.03	30.71±0.11
35	4-OH (C_6H_4)	37.7±0.16	38.94±0.12	39.7±0.16	40.97±0.14
36	3,4-OH (C_6H_3)	45.04±0.52	47.7±0.16	48.46±0.03	52.71±0.11
37	2,5-OH (C_6H_3)	77.33±0.02	79.7±0.16	76.65±0.03	77.47±0.13
38	2,3-OH (C_6H_3)	81.94±0.12	83.33±0.02	82.7±0.06	84.97±0.19
Standard= asc. acid[a]		–	–	15.08±0.03	16.09±0.17
Standard = donepezil[b]		15.08 ± 0.03	15.08±0.03	–	–

[c]Standard for DPPH and ABTS activities; [d]standard for AChE and BChE inhibitions

SAR for AChE and BChE inhibitions and antioxidant activities

SAR was discussed for all synthetic compounds which were screened for *in vitro* acetylcholinesterase, butyrylcholinesterase inhibitions and antioxidant (DPPH and ABTS) activities.

SAR for AChE and BChE inhibitory activities. Compounds **1**–**7**, **28** and **29** were halogen-substituted including F, Cl and Br. These compounds displayed inconsistent inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes. Of these, compound **2** with the *ortho*-chloro substitution was found to be the most potent AChE and BChE inhibitor with IC_{50} values of 23.08±0.03 and 26.08±0.43 µM, respectively. A comparison of the inhibitory activities of compounds **1** and **2** showed a positional effect on the inhibitory potential. Namely, in compound **1** the presence of chloro group at

Available on line at www.shd.org.rs/JSCS/

(CC) 2023 SCS.

para-position reduces the inhibitory activity, as shown by the IC_{50} values 35.04±0.20 μM for AChE and 37.13±0.18 μM for BChE enzymes. Correspondingly, in compounds **3** (IC_{50} = 24.94±0.12, 27.13±0.08 μM) and **4** (IC_{50} 24.57±0.07 and 27.57±0.07 μM), a slight decrease in the inhibitory potential was seen by the addition of chloro groups at the *ortho*-, *para*- and di-*ortho*-positions against AChE and BChE enzymes, respectively. However, the presence of chloro groups in compounds **5–7**, along with other groups such as NO_2 and OH, demonstrated lower potential against AChE and BChE enzymes. *para*-Bromo substituted compound **28** (IC_{50} 25.33±0.02 and 26.27±0.18 μM), exhibited pronounced activity against both AChE and BChE enzymes, respectively. However, compound **29** with trifluoromethyl substitution was found to be inactive against both enzymes which indicates that the trifluoromethyl group is not actively involved in the binding interaction to the active site of the enzyme (Fig. S-4 of the Supplementary material).

Quinazolinone derivatives as cholinesterase inhibitors show superior inhibitory activity compared to the standard drug tacrine. Among them, halogenated compounds showed potential activity against AChE and BChE enzymes. In our work, halogenated compounds showed potential activities when compared to the standard donepezil.

It has been found that the incorporation of methoxy substitutions in compounds **8–17** at different positions of aryl moiety (R) has a varying degree of inhibition. Among them, *ortho*-dimethoxy substituted compound **10** was found significantly active with IC_{50} of 26.94±0.12 and 27.99±0.09 μM for AChE and BChE enzymes, when compared to its *ortho*, *meta*-dimethoxy derivative compound **9**. Surprisingly, it was found that its *meta*-dimethoxy substituted positional isomer **8** was completely inactive. There might be a possibility that compound **8** attained such a conformation that does not fit well into the active site of the enzyme. However, when methoxy groups are present at the adjacent positions in compound **11** (IC_{50} 87.27±0.02 and 86.08±0.43 μM) a noticeable decline in the activity was observed when compared to compound **12** (IC_{50} 67.91±0.18, 69.02±0.11 μM), where an additional bromo group is present at *ortho*-position. The positional isomer of **11** *i.e.*, compound **13** demonstrated weak inhibitory potential against both enzymes. In the case of trimethoxy substituted derivatives (compounds **14** and **15**), a complete loss of activity was observed. This might be due to the steric hindrance and bulkiness of the groups. Compounds **16** with *para*-methoxy and *meta*-ethoxy substitutions displayed considerable inhibitory potential with IC_{50} of 27.57±0.07 and 29.13±0.18 μM against acetylcholinesterase and butyrylcholinesterase enzymes, respectively. In contrast, compound **17** was found to be inactive against both enzymes (Fig. S-5, Supplementary material). Compounds **18–24** and **32** with the combinations of ethoxy/methoxy and other substitutions such as OH, Cl, F and Br, exhibited moderate inhibition

(CC) 2023 SCS.

activities against both enzymes. *ortho*-Fluoro and *para*-methoxy substituted compound **22** was found to have relatively good activity in comparison to its other positional analogs. Compound **18** displayed IC_{50} values 27.91±0.18 and 27.91± ±0.18 μM against AChE and BChE enzymes, respectively. In contrast its positional isomer (compound **20**), compound **18** exhibited low inhibitory potential with IC_{50} of 51.41±0.12 and 53.33±0.02 μM against acetylcholinesterase and butyrylcholinesterase enzymes. The activity of the combination of Cl, Br and OH with methoxy substituted compounds **18**, **19**, **21**, **23**, **24** and **32**, displayed moderate to weak inhibitory activities which indicate that these groups are creating steric hindrance and less binding interaction in the enzyme's active site or their positive mesomeric effect is negatively contributing in the activity (Fig. S-6, Supplementary material).

Surprisingly, *ortho*, *meta* and *para* benzyloxy-substituted derivatives **25**–**27** were found to be inactive against acetylcholinesterase and butyrylcholinesterase enzymes. It might be due to bulky groups that do not favourably fit in the active site of the enzyme, which displayed that the presence of hydrophobic groups on the aryl part more specifically the presence of benzyloxy group, resulted in the loss of activity profile of compounds **25**–**27**, respectively. Exceptionally, thiophene substituted analogue **30** showed moderate activity against AChE and BChE enzymes with IC_{50} values 43.08±0.03 and 46.08±0.43 *μ*M, respectively (Fig. S-7, Supplementary material). Mono-hydroxyl substituted compounds **31**– –**35** showed good to moderate results against acetylcholinesterase and butyrylcholinesterase enzymes. The activity of five hydroxy-substituted derivatives, such as **31**–**35**, was different from each other against both enzymes. However, the structures of all five derivatives is very similar to each other but differ only in the position of hydroxyl at aryl part "R". Amongst them, compound **34** (IC_{50} 27.57±0.07 and 29.02±0.11 μM) has *ortho*-hydroxyl group exhibited better activity against AChE and BChE enzymes when compared with compounds **33** and **35**, respectively, which indicate that groups and position displayed significant role in the enzyme inhibition. However, compounds **31** and **32** with the combination of bromo and methoxy with a hydroxyl group, respectively, exhibited weak inhibitory activities against AChE and BChE enzymes. This activity pattern demonstrated the involvement of di-substituted hydroxy compounds **36**–**38**, which also displayed moderate to weak inhibitory activities. Compound **36** (IC_{50} 45.04±0.52 and 47.7±0.16 *μ*M) with *meta*, *para* di-hydroxy substitution showed better activity when compared to compounds **37** and **38** against acetylcholinesterase and butyrylcholinesterase enzymes (Fig. S-8, Supplementary material).

SAR for DPPH and ABTS radical scavenging activities. Based on SAR, the variations observed in DPPH and ATBS activities of quinazolinones **1**–**38** were discussed and compared against standard ascorbic acid with IC_{50} of 15.08±0.03 and 16.09±0.17 μM, respectively. Dichloro-substituted compound **4** showed

(CC) 2023 SCS.

DPPH (IC_{50} = 16.33 ± 0.02 μM) and ABTS (IC_{50} = 18.01 ± 0.12 μM) radical scavenging activities, respectively, and was found to be most active in the series. Its positional isomer (compound **3**) displayed a decline in activity against both radicals. However, mono-substituted compound **2** having chloro group at *meta* position (IC_{50} 17.65±0.23 and 19.47±0.03 μM), showed better DPPH and ABTS radical scavenging activities when compared to its positional isomer **1**. Antiradical activity depends on proton and electron transfer between the radical and the scavenging agent. Here 1,4 disubstituted chloro compounds seem to involve electron transfer and free radical scavenging, compared to monosubstituted and 1,3 disubstituted chloro compounds. The addition of hydroxyl and nitro substitution at aryl ring in compounds **5**–**7**, respectively, showed moderate to weak potential against DPPH and ABTS radical scavenging activities. The activity of di-methoxy substituted compounds **8**, **9** and **11**–**13** showed a further decrease in the activity when compared to *ortho*-dimethoxy substituted compound **10** which showed enhanced DPPH and ABTS radical scavenging activities. The addition of the methoxy group in compounds **14** and **15** further reduced the activity (Fig. S-9, Supplementary material). In the case of compound **16** (IC_{50} 30.04 ± 0.02 and 31.99±0.99 μM) with *para*-methoxy and *meta*-ethoxy groups showed better activities when compared to compound **17** (Fig. S-9). Another combination of methoxy with OH, Br, F and Cl substitutions in compounds **18**–**23** showed weak potential against DPPH and ATBS activities. Compounds **25–27** bearing benzyloxy substitution displayed decreased radical scavenging activities against DPPH and ATBS. The incorporation of bromo group as "R" in compound **28** with IC_{50} value 27.33 ± 0.02 and 28.01±0.12 μM, showed better potential than compound **31**. Mono-hydroxy and di-hydroxy substituted compounds **32**, **33**, **35** and **38** demonstrated good potential against DPPH and ABTS radical scavenging activities as compared to compound **34**. Compounds **23**, **29** and **30** showed a further decline in the activities as compared to the standard ascorbic acid (Fig. S-9).

Kinetic studies on acetylcholinesterase inhibitors

Kinetic studies on the most active AChE enzyme inhibitors (compounds **2**–**4**, **10**, **16**, **28** and **34**) were analysed to interpret the enzyme inhibition mechanisms by using graph fitting analysis in the Sigma-Plot enzyme kinetic software (Fig. S-10A and B, Supplementary material).

In 2,3-dihydroquinazolin-4(1*H*)-ones all the seven compounds (**2–4, 10, 16, 28** and **34**) acetylcholinesterase inhibition rate V_{max} and K_m were in the range of 60.5 to 79.8 μM min^{-1} mg^{-1} and 3.0 to 3.6 mM, respectively (Table II and Fig. S-10A). The *Ki* values were confirmed from the Dixon plot by plotting the reciprocal of the rate of reaction against different concentrations of compounds, where K_i values of all the eight compounds were in the range of 5.0 to 5.9 μM (Fig. S-10B). The inhibitor constant, K_i, is an indication of how potent an inhi-

Available on line at www.shd.org.rs/JSCS/

(CC) 2023 SCS.

bitor is; it is the concentration required to produce half maximum inhibition. In the uncompetitive type of inhibition, only V_{max} values are affected and no changes in K_m value. The low V_{max} and no effect in K_m value of these compounds indicated an uncompetitive type of inhibition.

TABLE II. Kinetic studies of active compounds for acetylcholinesterase inhibition; type of inhibition: uncompetitive

Cmpd. No.	V_{max} / μM min^{-1}mg^{-1}	K_m / mM	K_i / μM
2	79.8±1.2	3.2±0.01	5.2±0.1
3	70.4±1.0	3.6±0.02	5.4±0.2
4	60.5±2.2	3.0±0.01	5.5±0.5
10	66.8±1.8	3.3±0.02	5.8±0.1
16	71.0±1.2	3.1±0.01	5.0±0.2
28	65.4±1.0	3.2±0.02	5.3±o.1
34	53.2±2.2	3.4±0.01	5.9±02
Donepezil	62.0±1.0	3.0±0.01	5.1±0.1

Kinetic studies on butyrylcholinesterase inhibition

Kinetic studies on the most active AChE enzyme inhibitors compounds **2–4**, **10**, **16**, **28** and **34** were analysed to interpret their inhibition mechanisms (Fig. S-11, Supplementary material). In 2,3-dihydroquinazolin-4(*1H*)-ones the V_{max} and K_m of all the seven compounds were in the range of 80.3 to 85.4 μM min^{-1} mg^{-1} and 3.1 to 31.8 mM, respectively (Table III and Fig. S-11A). The K_i values were confirmed from the Dixon plot by plotting the reciprocal of the rate of reaction against different concentrations of compounds, where K_i values of all the five compounds were in the range of 10.3 to 10.9 μM (Fig. S-11B). The inhibitor constant, K_i, is an indication of how potent an inhibitor is; it is the concentration required to produce half maximum inhibition. In the competitive type of inhibition, only K_m values are affected and there are no changes in the V_{max} value. The high K_m and no effect in V_{max} of these compounds indicated a competitive type of inhibition.

TABLE III. Kinetic studies of active compounds for butyrylcholinesterase inhibition; type of inhibition: competitive

Cmpd. No.	V_{max} / μM min^{-1}mg^{-1}	K_m / mM	K_i / μM
2	82.0±2.2	3.1±0.2	10.6±0.5
3	80.3±2.7	9.2±0.1	10.4±0.3
4	82.2±5.3	20.2±0.2	10.7±0.2
10	85.4±1.2	2.1±0.1	10.6±0.4
16	82.0±1.4	3.7±0.2	10.4±0.1
28	84.1±2.4	31.8±0.1	10.3±0.1
34	82.5±2.9	4.7±0.1	10.9±02
Donepezil	80.1±1.6	13.5±0.1	10.2±0.1

Available on line at www.shd.org.rs/JSCS/

(CC) 2023 SCS.

Molecular docking (MD) studies

AChE and BChE MD study. MD was performed to explore the binding mode of the synthesized compounds against the targeted enzyme (AChE and BChE). MD results are in good agreement with the experimental results. We have noticed that compounds bearing the electron-withdrawing groups (EWGs) showed the best inhibitory activity against both targets. Interestingly, when compared with the other activity (α-amylase and α-glucosidase),[23] we have noted that the compounds bearing 1,3-dichlorobenzene showed high inhibitory potency when compared to 1-chlorobenzene. Similarly, the following compounds showed invert phenomena in the activity against both the targets. Those compounds bearing 1-chlorobenzene/1-bromobenzene substitution were found to be active. The protein–ligand interaction (PLI) profile was enlisted for all docked compounds in Tables S-IV and S-V of the Supplementary material.

Acetylcholinesterase (AChE) molecular docking study. The docking results for most active compound **2** against AChE revealed that the 3-methyl-tetrahydro pyrimidine-4(1*H*)-one moiety of the compound adopted several favourable interactions with catalytic residues (Fig. 1A, surface representation), including acidic residue Glu72, hydrophobic side chain Tyr334, Trp279 and Phe331, respectively (Fig. 1B). The reason for high potency might include the high number of adopted favourable interactions with catalytic residues. In the case of the 2nd ranked active compound **4**, where the substitution groups are the 2,3-dichloro, a similar interaction was observed. But the only difference so far found is; the active compound adopted π-stacking interaction with the 1-chloro moiety, whereas it lacks in the 2nd active compound (Fig. 1C). This might be one of the reasons for reduced activity in compound **4**. The PLI profile was enlisted for all docked compounds (Table S-IV).



Fig. 12. The PLI profile for synthesized compounds against the acetylcholinesterase (AChE) enzymes. A) The surface representation of the enzyme, B) the binding mode of the most potent compound **2** in the series and C) for compound **4**. A double-sided arrow represents the π-stacking.

Butyrylcholinesterase (BChE) molecular docking study. In the case of the docking results for most active compounds against BChE (Fig. S-2A) activity revealed that the compound bearing electron-withdrawing groups (EWG), *i.e.*,

(CC) 2023 SCS.

1-chlorobenzene (Fig. 2B) and 1-bromobenzene (Fig. 2C), *etc*., showed best inhibitory activity against the BChE enzyme. The PLI profile for the most active compound **2** and 2nd-ranked active compound **28** revealed an interesting observation that both the compound shared similar interaction with the hydrophobic residue Phe329. More interestingly, the most active compound **2** adopted interaction with the acidic residue Glu70 while compound **28** with Glu197, which suggested that might be these two residues play a vital role in enhancing the enzymatic activity. The hydrophobic residue Trp82, which is an active residue in the active site and play a vital role in the enzymatic activity, adopted two π-stacking interactions with the substituted benzene ring while the compound **28** is not capable of adapting interaction even though this residue is found in proximity with the 6-ring of the compound.



Fig. 2. The PLI profile for synthesized compounds against the butyrylcholinesterase (BChE) enzymes. A) The surface representation of the enzyme, B) the binding mode of the most potent compound **2** in the series and C) for compound **28**. The π-stacking is represented by a double-sided arrow.

Overall these results describe that the compounds bearing the EWG either at *ortho*- or *meta*-position displayed good inhibitory potential against the enzyme while others bearing both *ortho*- and *meta*- or *ortho*- and *para*-positions showed less activity. The PLI profiles were enlisted for all docked compounds in (Table S-V).

CONCLUSION

In the present study, compounds showed moderate to good inhibition against AChE, BChE, and antioxidant activities as compared with the standards donepezil and ascorbic acid, respectively. A structure-activity relationship was also established. *In silico* modeling studies revealed the binding mode of the quinazolinone derivatives. The kinetic studies on the seven most active compounds **2–4**, **10**, **16**, **28** and **34** were carried out. The compounds **2–4**, **10**, **16**, **28** and **34** were found to have an uncompetitive mode for acetylcholinesterase enzyme and the compounds **2–4**, **10**, **16, 28** and **34** were found to be in the competitive mode for butyrylcholinesterase enzymes.

(CC) 2023 SCS.

SUPPLEMENTARY MATERIAL

Additional data and information are available electronically at the pages of journal website: https://www.shd-pub.org.rs/index.php/JSCS/article/view/11370, or from the corresponding author on request.

Acknowledgement. The authors acknowledge the financial support of Sindh Higher Education Commission (SHEC), Pakistan *vide* letter No. NO.DD/SHEC/1-14/2014, Project Code SHEC/SRSP/Med-3/15/2021-21.

ИЗВОД

ИЗУЧАВАЊЕ ДЕРИВАТА 2,3-ДИХИДРОХИНАЗОЛИН-4(1*H*)-ОНА КАО ИНХИБИТОРА ХОЛИНЕСТЕРАЗА И ЊИХОВЕ АНТИОКСИДАТИВНЕ АКТИВНОСТИ: *IN VITRO*, *IN SILICO* И КИНЕТИЧКА ИСПИТИВАЊА

OLUWATOYIN BABATUNDE[1], SHEHRYAR HAMEED[1], KINGSLEY ADIBE MBACHU[1,2], FAIZA SALEEM[1], SRIDEVI CHIGURUPATI[3], ABDUL WADOOD[4], ASHFAQ UR REHMAN[4], VIJAYAN VENUGOPAL[5], KHALID MOHAMMED KHAN[1,7], MUHAMMAD TAHA[7], OLUSEGUN EKUNDAYO[2] и MARIA AQEEL KHAN[6]

[1]*H. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan,* [2]*Department of Chemistry, University of Ibadan, Nigeria,* [3]*Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraydah-52571, Saudi Arabia,* [4]*Department of Biochemistry, Computational Medicinal Chemistry Laboratory, UCSS, Abdul Wali Khan University, Mardan, Pakistan,* [5]*Faculty of Pharmacy, AIMST University, Kedah-08100, Malaysia,* [6]*Third World Center for Science and Technology, H. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan и* [7]*Department of Clinical Pharmacy, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam, 31441, Saudi Arabia*

Током истраживања нових активних инхибитора холинестераза и антиоксидативних агенаса, испитивани су синтетички деривати дихидрохиназолин-4(1*H*)-она **1–38** као потенцијални агенси за третман Алцхајмерове болести инхибицијом ацетилхолин-естеразе (AChE), бутирлихолин-естеразе (BChE) и као хватачи слободних радикала (DPPH и ABTS). Доминантан утицај на инхибицију ензима и способност хватања слободних радикала имају супституенти на ароматичном језгру. На основу резултата испитивања кинетике закључено је да једињења делују некопетентивним механизмом инхибиције. Молекулским моделовањем су испитане могуће интеракције током везивања кcallиназолинских деривата у активним местима оба ензима.

(Примљено 6. новембра 2021, ревидирано 17. маја 2022, прихваћено 2. фебруара 2023)

REFERENCES

1. S. Kumar, D. S. Brijeshlata, S. Dixit, *Int. J. Pharm. Bio. Sci.* **3** (2012) 59 (https://www.mendeley.com/catalogue/e895c115-5ca8-3d1b-956e-0477555aecc6/Int-J-Pharma-Bio-Sci)
2. B. Desgranges, J. C. Baron, V. de la Sayette, M. C. Petit-Taboue, K. Benali, B. Landeau, F. Eustache, *J. Neurol*. **121** (1998) 611 (https://doi.org/10.1093/brain/121.4.611)
3. R. M. Lane, S. G. Potkin, A. Enz, *Int. J. Neuropsychopharmacol*. **9** (2006) 101 (https://doi.org/10.1017/S1461145705005833)
4. T. Zhao, K. M. Ding, L. Zhang, X. M. Cheng, C. H. Wang, Z. T. Wang, *J. Chem.* (2013) 717232 (https://doi.org/10.1155/2013/717232)

(CC) 2023 SCS.

5. H. Guo, S. Albrecht, M. Bourdeau, T. Petzke, C. Bergeron, A. C. LeBlanc, *Am. J. Clin. Pathol*. **165** (2004) 523 (https://doi.org/10.1016/S0002-9440(10)63317-2)
6. S. Kumar, *Ind. J. Pharmacol.* **47** (2015) 444 (https://doi: 10.4103/0253-7613.161274)
7. N. H. Greig, D. K. Lahiri, K. Sambamurti, *Int. Psychogeriatr*. **14** (2002) 77 (https://doi.org/10.1017/S1041610203008676)
8. M. Asif, *Int. J. Med. Chem*. (2014) 395637 (https://doi.org/10.1155/2014/395637)
9. E. Jafari, M. R. Khajouei, F. Hassanzadeh, G. H. Hakimelahi, G. A. Khodarahmi, *Res. Pharm. Sci*. **11** (2016) 1 (https://www.mendeley.com/catalogue/fde6c1f7-4ecf-310e-b761-c9a2f037543e/Res-Pharm-Sci)
10. S. K. Wahan, B. Sharma, P. A. Chawla, *J. Heterocycl. Chem*. **59** (2022) 239 (https://doi.org/10.1002/jhet.4382)
11. D. Wang, F. Gao, *Chem. Cent. J*. **7** (2013) 1 (https://doi.org/10.1186/1752-153X-7-95)
12. P. S. Auti, G. George, A. T. Paul, *RSC Adv*. **10** (2020) 41353 (https://doi.org 10.1039/D0RA06642G)
13. S. S. AlNeyadi, N. Amer, T. G. Thomas, R. Al Ajeil, P. Breitener, N. Munawar, *Heterocycl. Comm*. **26** (2020) 112 (https://doi.org/10.1515/hc-2020-0112)
14. K. N. Mohana, C. B. P. Kumar, *Int. Scholarly Res. Notices* (2013) 620718 (https://doi.org/10.1155/2013/620718)
15. F. Z. Fang, S. Yang, G. Wu, *Nutr*. **18** (2002) 872 (https://doi.org/10.1016/S0899-9007(02)00916-4)
16. S. Cuzzocrea, D. P. Riley, A. P. Caputi, D. Salvemini, *Pharmacol. Rev*. **53** (2001) 135 (https://www.mendeley.com/catalogue/a54c6abb-aa6e-343f-91cf-06f546524153/Pharmacol-Rev)
17. A. Choudhary, R. Sharma, M. Nagar, M. Mohsin, H. S. Meena, *J. Chil. Chem. Soc*. **56** (2011) 911 (http://dx.doi.org/10.4067/S0717-97072011000400019)
18. F. Rahim, M. T. Javed, H. Ullah, A. Wadood, M. Taha, M. Ashraf, K. M. Khan, *Bioorg. Chem.* **62** (2015) 106 (https://doi.org/10.1016/j.bioorg.2015.08.002)
19. M. A. Abbasi, M. Ilyas, A. Sonia, D. Shahwar, M. A. Raza, K. M. Khan, N. Ambreen, *Sci. Iran* **19** (2012) 1580 (https://doi.org/10.1016/j.scient.2012.10.014)
20. K. Mohammed Khan, U. Rasool Mughal, N. Ambreen, N. Hasan Rama, F. Naz, S. Perveen, M. Iqbal Choudhary, *Lett. Drug Des. Discov*. **7** (2010) 716 (https://www.mendeley.com/catalogue/e16f7904-d62c-3e15-9d04-773c212f8746/Lett-Drug-Des-Discov)
21. K. Mohammed Khan, M. Rani, N. Ambreen, A. Ejaz, S. Perveen, S. Moazzam Haider, W. Voelter, *Lett. Drug Des. Discov.* **9** (2012) 135 (https://www.mendeley.com/catalogue/42ad6641-237f-3505-b9af-9360184eee91/Lett-Drug-Des-Discov)
22. K. Javaid, S. M. Saad, S. Rasheed, S. T. Moin, N. Syed, I. Fatima, M. Choudhary, M, *Bioorg. Med. Chem*. **23** (2015) 7417 (https://doi.org/10.1016/j.bmc.2015.10.038)
23. O. Babatunde, S. Hameed, U. Salar, S. Chigurupati, A.Wadood, A. U. Rehman, S. Perveen, *Mol. Divers.* (2021) 1 (https://doi.org/10.1007/s11030-021-10196-5).
24. K. M. Khan, S. M. Saad, N. N Shaikh, S. Hussain, M. I Fakhri, S. Perveen, S. M. I. Choudhary, *Bioorg. Med. Chem.* **22** (2014) 3449 (https://doi.org/10.1016/j.bmc.2014.04.039)
25. S. Perveen, S. M. Saad, S. Perveen, A. Hameed, M. T. Alam, K. M. Khan, M. I. Choudhary, *J. Chem. Soc. Pak.* **38** (2016) (https://www.mendeley.com/catalogue/ecd7844f-d565-3fcd-8bb0-28a836aefd53/J-Chem-Soc-Pak)

(CC) 2023 SCS.

26. G. L. Ellman, K. D. Courtney, Jr. V. Andres, R. M. Featherstone, *Biochem. Pharmacol.* **7** (1961) 88 (https://doi.org/10.1016/0006-2952(61)90145-9)
27. P. Molyneux, Songklanakarin, *J. Sci. Technol*. **26** (2004), 211
28. M. S. Blois, *Nature* **181** (1958) 1199 (https://doi.org/10.1038/1811199a0)
29. U. Kulsoom, U. Salar, K. M. Khan, S. Chigurupati, S. Syed, A. Wadood, A. Ur Rehman, B. Fatima, F. Saleem, M. Taha, S. G. Felemban, S. R. Dachani, S. Perveen, *Monatsh. Chem*. **153** (2022) 949 (https://doi.org/10.1007/s00706-022-02972-2)
30. R. Re, N. Pellegrini, A. Proteggente, A. Pannala, M. Yang, C. Rice-Evans, *Free Radic. Biol. Med*. **26** (1999) 1231 (https://doi.org/10.1016/S0891-5849(98)00315-3)
31. Molecular Operating Environment (MOE), 2016.08; Chemical Computing Group Inc., Montreal, QC, 2016 (https://www.mendeley.com/catalogue/89d1dadd-e734-39ed-beda-f3d9995d868b/Montreal-QC-Canada)
32. S. Di Giovanni, A. Borloz, A. Urbain, A. Marston, K. Hostettmann, P. A. Carrupt, M. Reist, *Eur. J. Pharm. Sci.* **33** (2008) 109 (https://doi.org/10.1016/j.ejps.2007.10.004).

(CC) 2023 SCS.